Esketamine Repurposing

The company is repurposing Johnson & Johnson's approved esketamine treatment Spravato, aiming to tap into a substantial commercial opportunity in alcohol use disorder, which affects approximately 15 million American adults. Tennyson highlighted that this market is significantly larger than the current indication for treatment-resistant depression.